These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 11820413

  • 1. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
    Raitanen MP, Aine R, Kylmälä T, Kallio J, Liukkonen T, Tammela T, Finnbladder Group.
    Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
    [Abstract] [Full Text] [Related]

  • 2. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP, Leppilahti M, Tuhkanen K, Forssel T, Nylund P, Tammela T, FinnBladder Group.
    Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
    [Abstract] [Full Text] [Related]

  • 3. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
    Raitanen MP, Aine RA, Kaasinen ES, Liukkonen TJ, Kylmälä TM, Huhtala H, Tammela TL, Finnbladder Group.
    Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
    [Abstract] [Full Text] [Related]

  • 4. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL, Martín García B, de Diego Rodríguez E, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, del Valle Schaan JI, Roca Edreira A, Rado Velázquez MA.
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [Abstract] [Full Text] [Related]

  • 5. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
    Ianari A, Sternberg CN, Rossetti A, Van Rijn A, Deidda A, Giannarelli D, Pansadoro V.
    Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
    [Abstract] [Full Text] [Related]

  • 6. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C.
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [Abstract] [Full Text] [Related]

  • 7. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002 Aug; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
    Leyh H, Mazeman E.
    Eur Urol; 1997 Aug; 32(4):425-8. PubMed ID: 9412800
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Noninvasive detection of bladder cancer with the BTA stat test.
    Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I.
    J Urol; 1999 Feb; 161(2):443-6. PubMed ID: 9915422
    [Abstract] [Full Text] [Related]

  • 12. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 13. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ.
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [Abstract] [Full Text] [Related]

  • 14. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP, FinnBladder Group.
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
    Leyh H, Hall R, Mazeman E, Blumenstein BA.
    Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 18. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors].
    Gregersen B, Mommsen S, Svanholm H.
    Ugeskr Laeger; 1999 Apr 05; 161(14):2071-3. PubMed ID: 10354792
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.